SCHEMBL562232

SCHEMBL562232

CC(OCc1ccccc1)C(N)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 10/20 0.68
SLC1A2 P43004 9/20 0.68
SLC1A3 P43003 8/20 0.68
MEN1 O00255 1/20 0.68
CYP1A2 P05177 1/20 0.68
CYP2D6 P10635 1/20 0.68
CYP2C9 P11712 1/20 0.68
CYP2C19 P33261 1/20 0.68
KMT2A Q03164 1/20 0.68
SLC15A1 P46059 1/20 0.49
MMP9 P14780 2/20 0.47
MMP8 P22894 2/20 0.47
ALDH1A1 P00352 1/20 0.46
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
SLC7A5 Q01650 1/20 0.46
LTA4H P09960 1/20 0.44
RCE1 Q9Y256 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288385 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL31606672 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL18325959 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL14037383 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL289127 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL8464720 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
SCHEMBL288386 1.00 SLC1A1 (0.68) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
Hydrochloric Acid SCHEMBL20820005 0.98 SLC1A1 (0.66) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
Hydrochloric Acid SCHEMBL15670199 0.98 SLC1A1 (0.66) SLC1A1SLC1A2SLC1A3MEN1CYP1A2
Hydrochloric Acid SCHEMBL3334189 0.98 SLC1A1 (0.66) SLC1A1SLC1A2SLC1A3MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116655730-A Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases 雅斯娜 2023-08-29 CN claimed
CN-114805487-A Polypeptide compound and application thereof 成都诺和晟泰生物科技有限公司 2022-07-29 CN claimed
CN-113045625-A Polypeptide as growth hormone secretagogue receptor agonist and application thereof 成都诺和晟泰生物科技有限公司 2021-06-29 CN claimed
EP-2722051-A1 Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus Seattle Genetics, Inc. (US) 2014-04-23 EP claimed
CN-102503850-A Hydroxyl-contained N-acylamino acid and preparation method thereof UNIV TIANJIN 2012-06-20 CN claimed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 US claimed
EP-1917020-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS Seattle Genetics, Inc. (US) 2008-05-07 EP claimed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 WO claimed
EP-0709373-B1 PYRROLIDINE DERIVATIVE ZAIDAN HOJIN BISEIBUTSU (JP) 2001-10-17 EP claimed
US-5753619-A CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) 1998-05-19 US claimed
EP-0714909-A1 Composition for prophylaxis or treatment of pulmonary circulatory diseases Takeda Chemical Industries, Ltd. (JP) 1996-06-05 EP claimed
EP-0272671-B1 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD (CH) 1994-03-16 EP claimed
US-5055451-A Prevent tissue damage SYNTEX INC. (US) 1991-10-08 US claimed
EP-0272671-A2 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD. (CH) 1988-06-29 EP claimed
US-4483807-A Process for producing a slow release composite JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) 1984-11-20 US claimed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2025-12-02 US disclosed
US-4127532-A ANALGESIC VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY 1978-11-28 US disclosed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 SLC1A1 1052/4885SLC1A2 731/4885SLC1A3 805/4885
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus MMAB, DNPEP, MARCKS SLC1A1 293/4885SLC1A2 571/4885SLC1A3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.